May 8, 2025 02:18 PM EDTUpdated May 9, 09:41 AM
Pharma
Law

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

Alexis Kramer

Deputy Editor

As­traZeneca lost its chal­lenge to Medicare drug price ne­go­ti­a­tions in the first ap­peals court rul­ing on the mer­its of the Biden-era pro­gram.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Broad In­sti­tute con­ducts lay­offs as it preps for cuts in fed­er­al fund­ing; Dyne’s fi­nanc­ing

Pfiz­er ends Phase 1b/2 tri­al for fi­nal Tril­li­um CD47 drug

Kevin Tang's Con­cen­tra snags an­oth­er buy­out, this time for IGM Bio­sciences

PBM re­forms fail to make the cut as Sen­ate pass­es Trump’s mega­bill

Un­nat­ur­al Prod­ucts taps ar­genx's help for ringed mol­e­cules, ex­pands in­ter­nal work in­to obe­si­ty

A service from the Financial Times